SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ImmunoGen -- Ignore unavailable to you. Want to Upgrade?


To: rjk01 who wrote (5496)5/25/2012 4:46:31 PM
From: Gary Mohilner  Read Replies (1) | Respond to of 5665
 
I never doubted they'd get the notice, but now they have 6 months, and if needed they can ask for 6 more, I'm hopeful that they won't need the extension. I actually did trade 100 shares of IMGN for nearly 3000 shares of AEZS this week. I still strongly believe IMGN could double by the end of next year, but if I'm right about AEZS in the same time it could be a ten banger or more. Frankly if the peek into the MM Trial for Perifosine results in continuing that trial, I think $1 to $2 could result from that alone, but before that happens at least the NDA for AEZS-130 should be filed, that ought to take the price above $1.

The potentially biggest news for AEZS this year, IMHO, is if AEZS-130 works for Cancer Cachexia or not. If it does, what's currently thought of as a niche drug might truly reach blockbuster potential. I don't believe the company will partner the drug until they know. If Cachxia becomes part of the mix, I believe this is a potential partnership that's worth hundreds of millions up front if partnered worldwide to a single big Pharma partner.

As for IMGN, I just read that Roche is being very public about its ASCO presentations, with an emphasis on T-DM1 which will be featured in a major oral presentation. I believe we could see highs not seen in over 10 years post ASCO. As we learn more about other drugs in the clinic, I believe awareness will grow of the breadth of IMGN's pipeline and with approval of T-DM1 and other drugs approaching or in Pivotal Trials, I believe new all time highs for IMGN quite possible. Not this year, but let's see where we are at ASCO 2013.

Gary